A new study shows that the controversial drug hydroxychloroquine touted by former President Donald Trump increased the survival rate of severely ill coronavirus patients.
The observational study, published by medRxiv, found that antimalarial drug hydroxychloroquine, along with zinc, could increase the coronavirus survival rate by as much as nearly 200% if distributed at higher doses to ventilated patients with a severe version of the illness.
“We found that when the cumulative doses of two drugs, HCQ and AZM, were above a certain level, patients had a survival rate 2.9 times the other patients,” the study’s conclusion states.
The study adds, “By using causal analysis and considering of weight-adjusted cumulative dose, we prove the combined therapy, >3 g HCQ and > 1g AZM greatly increases survival in Covid patients on IMV and that HCQ cumulative dose > 80 mg/kg works substantially better. These data do not yet apply to hospitalized patients, not on IMV. Since those with higher doses of HCQ had higher doses of AZM, we cannot solely attribute the causal effect to HCQ/AZM combination therapy. However, it is likely AZM does contribute significantly to this increase in survival rate. Since higher dose HCQ/AZM therapy improves survival by nearly 200% in this population, the safety data are moot.”
The study was conducted by Saint Barnabas Medical Center in New Jersey on 255 patients.
Read the full story on Washington Examiner
License All rights reserved by arlecoproducciones